SC
JAZZ icon

Solstein Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Solstein Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-21
Closed -$2.58K – 317
2023
Q4 		$2.58K Hold
21
– – ﹤0.01% 287
2023
Q3 		$2.72K Hold
21
– – ﹤0.01% 286
2023
Q2 		$2.6K Hold
21
– – ﹤0.01% 285
2023
Q1 		$3.07K Hold
21
– – ﹤0.01% 252
2022
Q4 		$3.35K Hold
21
– – ﹤0.01% 263
2022
Q3 		$3K Hold
21
– – ﹤0.01% 278
2022
Q2 		$3K Hold
21
– – ﹤0.01% 317
2022
Q1 		$3K Sell
21
-63
-75% -$9.14K ﹤0.01% 350
2021
Q4 		$11K Hold
84
– – 0.01% 316
2021
Q3 		$11K Hold
84
– – 0.01% 352
2021
Q2 		$15K Buy
+84
New +$14.6K 0.02% 294

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Solstein Capital's JAZZ Position: Q1 2024 in Review

Solstein Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2024, closing a stake of 21 shares — an estimated $2.58K sold.

Solstein Capital first reported a position in JAZZ in Q2 2021 and held it in 11 quarters. The position peaked at $15K in Q2 2021. 481 funds tracked by Wall St. Rank hold JAZZ as of Q1 2024.

  • Solstein Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Solstein Capital sold 21 Jazz Pharmaceuticals shares in Q1 2024, an estimated $2.58K.
  • Solstein Capital first reported a position in Jazz Pharmaceuticals in Q2 2021 and held it in 11 quarters.
  • Solstein Capital's Jazz Pharmaceuticals position peaked at $15K in Q2 2021.
  • 481 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2024.

Based on Solstein Capital's 13F filing for Q1 2024, filed 24 Apr 2024.